SBIR/STTR Research Award
Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists
Award amount
$347,546Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Bohemica Pharmaceuticals, LLC
- Proposal award date
- 2016-06-15
- Contract end date
- 2019-06-14
- UEI
- Not reported
- Solicitation number
- PA14-308
- Topic code
- 100
Research abstract
DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of CXCR chemokine receptor The objective of this year Phase I project is to use the PCX platform to develop an innovative combination treatment of cholangiocarcinoma using PCX microRNA nanoparticles Clinical and experimental studies show that CXCR expression is associated with more aggressive disease higher primary tumor burden more metastases and shorter overall survival in cholangiocarcinoma The hypothesis of this project is that using PCX to deliver miR b inhibitor identified in our preliminary studies s potential target in cholangiocarcinoma will lead to improved overall anticancer activity We will accomplish the objectives through pursuing the following specific aims optimize PCX microRNA formulation parameters to obtain nanoparticles capable of simultaneous CXCR inhibition and microRNA delivery in cholangiocarcinoma and determine if delivery of miR b inhibitor by PCX improves overall survival in orthotopic rat model of cholangiocarcinoma The approach is innovative because of the dual function design of nanoparticles with CXCR inhibitory activity and microRNA delivery The proposed research is significant because it will establish widely applicable and versatile NA delivery platform that target chemokine networks as a way of improving therapeutic outcomes in cancer and other diseases with involvement of CXCR
PUBLIC HEALTH RELEVANCE Nucleic acids represent a class of promising therapeutic agents in a broad range of diseases To take full advantage of these new therapeutics there is a critical need to develop reliable and efficient delivery methods The proposed research is relevant to public health because it will address the need for such methods by developing unique dual function nanoparticles to deliver microRNA as a way of treating a deadly form of liver cancer
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- First-in-class TREM-1 inhibitors for neovascular retinal diseases
- Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome
- Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids
- Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease
- Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturing